CA2502479A1 - Molecule de liaison a un recepteur de la laminine - Google Patents

Molecule de liaison a un recepteur de la laminine Download PDF

Info

Publication number
CA2502479A1
CA2502479A1 CA002502479A CA2502479A CA2502479A1 CA 2502479 A1 CA2502479 A1 CA 2502479A1 CA 002502479 A CA002502479 A CA 002502479A CA 2502479 A CA2502479 A CA 2502479A CA 2502479 A1 CA2502479 A1 CA 2502479A1
Authority
CA
Canada
Prior art keywords
cys
thr
seq
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002502479A
Other languages
English (en)
Inventor
Unknown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Procyon Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2488777 external-priority patent/CA2488777A1/fr
Application filed by Procyon Biopharma Inc filed Critical Procyon Biopharma Inc
Priority to CA002502479A priority Critical patent/CA2502479A1/fr
Priority to PCT/CA2005/001831 priority patent/WO2006058431A1/fr
Priority to EP05815992A priority patent/EP1833501A4/fr
Priority to CA002591301A priority patent/CA2591301A1/fr
Publication of CA2502479A1 publication Critical patent/CA2502479A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002502479A 2004-12-01 2005-04-15 Molecule de liaison a un recepteur de la laminine Abandoned CA2502479A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002502479A CA2502479A1 (fr) 2004-12-01 2005-04-15 Molecule de liaison a un recepteur de la laminine
PCT/CA2005/001831 WO2006058431A1 (fr) 2004-12-01 2005-12-01 Molecule de liaison au recepteur de la laminine
EP05815992A EP1833501A4 (fr) 2004-12-01 2005-12-01 Molecule de liaison au recepteur de la laminine
CA002591301A CA2591301A1 (fr) 2004-12-01 2005-12-01 Molecule de liaison au recepteur de la laminine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,488,777 2004-12-01
CA 2488777 CA2488777A1 (fr) 2004-12-01 2004-12-01 Molecule liante de recepteur de laminine
CA002502479A CA2502479A1 (fr) 2004-12-01 2005-04-15 Molecule de liaison a un recepteur de la laminine

Publications (1)

Publication Number Publication Date
CA2502479A1 true CA2502479A1 (fr) 2006-06-01

Family

ID=36564723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002502479A Abandoned CA2502479A1 (fr) 2004-12-01 2005-04-15 Molecule de liaison a un recepteur de la laminine

Country Status (3)

Country Link
EP (1) EP1833501A4 (fr)
CA (1) CA2502479A1 (fr)
WO (1) WO2006058431A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861710A (en) * 1986-09-26 1989-08-29 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA clone encoding laminin receptor
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
CN1286697A (zh) * 1998-12-10 2001-03-07 上海第二医科大学 Npcahh01:人跨膜蛋白e3-16基因
CA2355334A1 (fr) * 2000-10-16 2002-04-16 Procyon Biopharma Inc. Preparations pharmaceutiques et methodes visant a inhiber la croissance de tumeurs
CA2361736A1 (fr) * 2001-11-08 2003-05-08 Unknown Psp94 : utilisation dans le traitement de l'hypercalcemie et de la metastase osseuse

Also Published As

Publication number Publication date
WO2006058431A1 (fr) 2006-06-08
EP1833501A1 (fr) 2007-09-19
EP1833501A4 (fr) 2009-09-16

Similar Documents

Publication Publication Date Title
JP4634614B2 (ja) 結合組織成長因子(ctgf)断片とそれを用いた方法および使用
ES2363765T3 (es) Agonistas de fgfr.
US20100158907A1 (en) Connective tissue growth factor fragments and methods and uses thereof
JP2008509157A (ja) 抗血管新生ペプチドおよびその使用方法
AU2015359043C1 (en) Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
EP3366695B1 (fr) Peptides dérivés de la saposine-a et leurs utilisations
WO2004016230A2 (fr) Identification du recepteur endothelial du domaine kringle-5 de l'angiostatine
US20020077289A1 (en) Angiostatin and endostatin binding proteins and methods of use
WO2012090207A2 (fr) Peptides par1 et par2 de queue c et mimétiques peptidiques
EP1332761A1 (fr) Agonistes des récepteurs du facteur de croissance des fibroblastes
CA2502479A1 (fr) Molecule de liaison a un recepteur de la laminine
CA2591301A1 (fr) Molecule de liaison au recepteur de la laminine
CA2488777A1 (fr) Molecule liante de recepteur de laminine
Tiemann et al. Detection of the three Kunitz-type single domains of membrane-bound tissue factor pathway inhibitor (TFPI) by flow cytometry
US20100215583A1 (en) Cell nucleus-entering compositions
CA2361736A1 (fr) Psp94 : utilisation dans le traitement de l'hypercalcemie et de la metastase osseuse
US20080182777A1 (en) Regulation of cell migration and adhesion
CA2485138C (fr) Gene pmepa1 regule par les androgenes et procedes d'utilisation de ce dernier pour inhiber la croissance des cellules cancereuses
CA2429404A1 (fr) Utilisation d'un compose antagoniste de la proteine esm-1 pour la fabrication d'un medicament pour le traitement d'un cancer
CZ20013222A3 (cs) Protein, peptid, protilátka, způsob výroby a farmaceutický prostředek
EP1765852A1 (fr) Procede et composition pour le traitement de l'angiogenese et pour la prevention de la progression du cancer et de metastases comprenant un membre de la famille des proteines secretees par la prostate (psp94)

Legal Events

Date Code Title Description
FZDE Dead